Q4 Results are out! As the Nifty 50 companies line up to disclose their performance report, we bring you a summary of their results along with the schedule of the results to come. (check out the earlier post here)
Here is what PS Jayakumar, Managing Director & CEO had to say, “The year 2015-16 has been one of transformation addressing NPAs. We are excited by the transformation journey we have embarked on, which will give us leadership position in the banking and financial services sector.
Received two final approvals and one tentative approval of the NDAs filed by the Proprietary Products Business. Zembrace launched in April 2016.
Gross Profit Margin at 59.6%, improved by 200 bps over last year.
Research & Development (R&D) spend at Rs. 17.8 billion, 11.5% of revenues. Continued focus on building complex generics and differentiated products pipeline.
Here is what G V Prasad, CEO and co-chairman of the company had to say, “It’s been a challenging quarter for Dr Reddy’s. While there has been a marginal decline in revenue, there has been a great impact on profitability. This is mainly due to the provision, made as a matter of actively abundant precaution, to write down our outstanding receivables from Venezuela. We will continue to actively engage with the Venezuelan government to provide affordable medicine to fulfil the need of people of the country, subject to repatriation of funds.”
Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.